Transcept shares soar on revived NDA hopes for Intermezzo

Shares of Transcept Pharmaceuticals ($TSPT) shot up more than 70% after the biotech laid out plans to resubmit its sleep drug Intermezzo to the FDA--after the agency green-lighted its plan to adjust dosing based on gender and fine-tune the timing instructions on the label.

Transcept was handed a rejection on Intermezzo a few months ago after regulators raised a red flag that the drug--a reformulated, sublingual version of Ambien (zolpidem tartrate)--could be unsafe for some patients who used it in the middle of the night. The agency felt that any residual levels of the drug could interfere with driving--a key safety hurdle for many new insomnia treatments.

The biotech's response was to agree to reduce the dosing level for women--from 3.5 mg to 1.75 mg--keep the same dose for men and add to the amount of time a person would need to wait before getting behind the wheel after taking a dose. And the FDA's approach, Transcept added, would allow the biotech to resubmit the app this month without additional trials and with the prospect of a two-month review.

That formula seemed just right for some of the company's backers, who started pushing up the stock price in after-hours trading.

- check out the Transcept release
- read the story from the Wall Street Journal

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.